Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TS-172 in Healthy Adults
NCT04979572Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TS-172 in hyperphosphatemia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Aug 2021; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT04979572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979572.